Relentless cycles of contraction‑induced muscle injury and incomplete repair are a hallmark of Duchenne Muscular Dystrophy (DMD), a severe X‑linked myopathy caused by dystrophin gene mutations that drive progressive muscle wasting. In the absence of functional dystrophin, sarcolemmal integrity is profoundly compromised, rendering myofibers mechanically fragile and promoting ongoing necrosis with maladaptive regeneration. Within this environment, muscle satellite cells (MuSCs)—the resident stem cells that normally transition from quiescence to activation, proliferation, and differentiation to rebuild damaged fibers—become intrinsically impaired. Rather than generating sufficient committed myogenic progenitors, dystrophic MuSCs show a pathological bias toward self‑renewal at the expense of differentiation, further limiting effective repair.
Recent studies identify caspase‑3 as a central regulator of satellite cell fate. Beyond its classical role in apoptosis, caspase‑3 has non‑apoptotic functions that actively support skeletal muscle differentiation. By cleaving Pax7, a transcription factor required to maintain satellite cell stemness, caspase‑3 restricts self‑renewal and promotes entry into the myogenic program. In this study, the small‑molecule procaspase activator PAC‑1 was used to enhance caspase‑3 activity in dystrophic muscle. PAC‑1 treatment robustly increased expression of the myogenic regulatory factors MyoD and Myogenin, consistent with enhanced satellite‑cell differentiation. PAC‑1 also induced cleavage of protein kinase C zeta (PKCζ), implicating PKCζ as a downstream effector of caspase‑3–mediated fate decisions, and led to more pronounced asymmetric segregation of phosphorylated PKCζ in paired MuSCs.
Together, these findings support a mechanistic model in which carefully controlled caspase‑3 activation shifts satellite cell fate toward differentiation rather than self‑renewal. Exploiting this pathway offers a strategy to correct intrinsic MuSC dysfunction in DMD, thereby improving muscle regeneration and functional recovery. Ongoing work will evaluate PAC‑1 in dystrophic mouse models using immunostaining, histopathology, and muscle performance assays to further validate its therapeutic potential. Overall, pharmacological stimulation of caspase‑3 with PAC‑1 emerges as a promising regenerative approach to restore efficient myogenesis and improve outcomes for individuals with Duchenne Muscular Dystrophy.